AR120358A1 - RECOMBINANT CDKL5 PROTEINS, GENE THERAPY AND PRODUCTION METHODS - Google Patents

RECOMBINANT CDKL5 PROTEINS, GENE THERAPY AND PRODUCTION METHODS

Info

Publication number
AR120358A1
AR120358A1 ARP200103015A ARP200103015A AR120358A1 AR 120358 A1 AR120358 A1 AR 120358A1 AR P200103015 A ARP200103015 A AR P200103015A AR P200103015 A ARP200103015 A AR P200103015A AR 120358 A1 AR120358 A1 AR 120358A1
Authority
AR
Argentina
Prior art keywords
cdkl5
recombinant
gene therapy
proteins
production methods
Prior art date
Application number
ARP200103015A
Other languages
Spanish (es)
Inventor
Sean Clark
Sean Sullivan
Hilary Gray
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of AR120358A1 publication Critical patent/AR120358A1/en

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen composiciones para terapia génica con CDKL5, así como también las proteínas CDKL5 recombinantes. Dichas composiciones para terapia génica con CDKL5 y/o proteínas recombinantes pueden incorporar polipéptidos que penetran en la célula y/o polipéptidos señal líder. También se proveen métodos para producir dichas composiciones para terapia génica y proteínas CDKL5 recombinantes, así como también, las composiciones farmacéuticas, métodos de tratamiento y usos de las composiciones de terapia génica y proteínas CDKL5 recombinantes.Compositions for CDKL5 gene therapy are provided, as well as recombinant CDKL5 proteins. Such gene therapy compositions with CDKL5 and/or recombinant proteins may incorporate cell-penetrating polypeptides and/or leader signal polypeptides. Methods for producing such recombinant CDKL5 protein and gene therapy compositions are also provided, as well as pharmaceutical compositions, methods of treatment, and uses of the recombinant CDKL5 protein and gene therapy compositions.

ARP200103015A 2019-10-30 2020-10-30 RECOMBINANT CDKL5 PROTEINS, GENE THERAPY AND PRODUCTION METHODS AR120358A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962928134P 2019-10-30 2019-10-30

Publications (1)

Publication Number Publication Date
AR120358A1 true AR120358A1 (en) 2022-02-09

Family

ID=80782229

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103015A AR120358A1 (en) 2019-10-30 2020-10-30 RECOMBINANT CDKL5 PROTEINS, GENE THERAPY AND PRODUCTION METHODS

Country Status (1)

Country Link
AR (1) AR120358A1 (en)

Similar Documents

Publication Publication Date Title
CL2022000300A1 (en) Interleukin 21 muteins and their uses for treating solid tumors (divisional of application no. 202000252)
EA201892561A1 (en) HYBRID PROTEINS GDF15 AND THEIR APPLICATION
BR112017018975A2 (en) fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for il15ra and therapeutic uses thereof.
SA518400424B1 (en) Antibody molecules for cancer treatment
BR112021022874A2 (en) epcam binding proteins and methods of use
CO2019002609A2 (en) Recombinant binding proteins and their uses
BR112019001099A2 (en) uses of extracellular vesicles comprising a fusion protein having fc binding capacity
AR115389A1 (en) CD73 ANTAGONIST ANTIBODY
MX2020009371A (en) Compositions and methods for tcr reprogramming using fusion proteins.
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
MX2020005670A (en) Cdkl5 expression variants and cdkl5 fusion proteins.
ECSP22019177A (en) NKG2D FUSION PROTEINS AND THEIR USES
BR112017018538A2 (en) eukaryotic expression vectors comprising regulatory elements of globin gene clusters
DOP2016000079A (en) RECOMBINANT GLICOPROTEINS AND ITS USES
BR112022006842A2 (en) VARIANT IGF2 CONSTRUCTS
BR112022008201A2 (en) SURFACE PROTEIN DEGRADATION USING B-SPECIFIC BINDING AGENT
BR112022003633A2 (en) Methods for producing recombinant human arginase 1 and uses thereof
BR112018077225A2 (en) tatk-cdkl5 fusion proteins, compositions, formulations and use thereof
AR120358A1 (en) RECOMBINANT CDKL5 PROTEINS, GENE THERAPY AND PRODUCTION METHODS
CL2020002507A1 (en) Variants of lfa3 and compositions and uses thereof
BR112022001945A2 (en) Protein motifs of rubisco binding and uses thereof
BR112017005573A2 (en) solubilized enzyme and its uses
AR114938A1 (en) EXPRESSION VARIANTS OF CDKL5 AND FUSION PROTEINS CDKL5
AR119984A1 (en) NKG2D FUSION PROTEINS AND THEIR USES
WO2021131944A8 (en) Cancer gene therapy drug

Legal Events

Date Code Title Description
FB Suspension of granting procedure